EMERYVILLE, Calif., Aug. 17, 2015 /PRNewswire/ -- Nanomix Inc., (Nanomix), a leading nanotechnology company focused on the development of next generation mobile diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, today announced the appointment of Larry K. Wray, Ph.D. as Vice President of Development. Dr. Wray, most recently VP of R&D at PerkinElmer, brings significant diagnostic product development and executive experience to Nanomix.
"We are very excited to have Larry join the Nanomix team", said David Ludvigson, President and CEO of Nanomix. "As we drive to the commercial launch of our first product, Larry's product development and management background will be important to the finalization of our products in development and in the expansion of our future offerings."
Dr. Wray has over 25 years of experience in the diagnostics industry including roles with PerkinElmer, Celera, Ventana Medical, and Abbott Laboratories. His experience includes product development of instrument, reagent, and software systems involving molecular diagnostics, immunoassays, and mass spectrometry, as both LDTs and IVDs. He has also been responsible for CE, FDA, and CFDA registrations. Dr. Wray holds a Ph.D. in Genetics from the University of Texas (Austin), an M.S. in Health and Medical Science from University of California (Berkeley), and was an NIH postdoctoral fellow at University of Pennsylvania.
For more information, visit: http://www.nano.com
5980 Horton St, Suite 600
Emeryville, CA 94608
SOURCE Nanomix Inc.